Diabetic Nephropathies

Nephrology
9
Pipeline Programs
9
Companies
9
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
2
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 11 programs with unclassified modality

On Market (2)

Approved therapies currently available

Boehringer Ingelheim
MICARDISApproved
telmisartan
Boehringer Ingelheim
Angiotensin 2 Receptor Blocker [EPC]oral1998
U
TELMISARTANApproved
telmisartan
Unknown Company
Angiotensin 2 Receptor Blocker [EPC]oral2014

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
5 programs
2
2
TelmisartanPhase 4Small Molecule1 trial
Telmisartan capsule 40 mgPhase 41 trial
BI 685509Phase 11 trial
BI 690517Phase 11 trial
Sodium-glucose cotransporter 2 inhibitorsN/A1 trial
Active Trials
NCT07444203Recruiting200Est. Nov 2028
NCT03165227Completed75Est. Dec 2019
NCT03165240Completed62Est. May 2020
+2 more trials
Providence Therapeutics
2 programs
1
SotagliflozinPhase 3Small Molecule1 trial
Mean blood glucoseN/A1 trial
Active Trials
NCT03334318CompletedEst. Dec 2021
NCT06217302RecruitingEst. May 2029
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Adalat XLPhase 31 trial
Active Trials
NCT00713011Withdrawn0Est. Mar 2009
Celularity
CelularityFLORHAM PARK, NJ
1 program
1
PDA-002Phase 21 trial
Active Trials
NCT02552277CompletedEst. Oct 2017
Regeneron
RegeneronTARRYTOWN, NY
1 program
Sodium-glucose cotransporter 2 inhibitorsN/A
Genentech
GenentechCA - Oceanside
1 program
Sodium-glucose cotransporter 2 inhibitorsN/A
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Sodium-glucose cotransporter 2 inhibitorsN/A
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Sodium-glucose cotransporter 2 inhibitorsN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Boehringer IngelheimTelmisartan
Boehringer IngelheimTelmisartan capsule 40 mg
Providence TherapeuticsSotagliflozin
BayerAdalat XL
CelularityPDA-002
Boehringer IngelheimBI 685509
Boehringer IngelheimBI 690517
Boehringer IngelheimSodium-glucose cotransporter 2 inhibitors
Providence TherapeuticsMean blood glucose

Clinical Trials (9)

Total enrollment: 1,749 patients across 9 trials

NCT00153023Boehringer IngelheimTelmisartan

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Start: Apr 2003Est. completion: Dec 2005885 patients
Phase 4Completed
NCT00153088Boehringer IngelheimTelmisartan capsule 40 mg

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Start: Jan 2003Est. completion: Nov 2005527 patients
Phase 4Completed
NCT06217302Providence TherapeuticsSotagliflozin

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Start: Oct 2024Est. completion: May 2029
Phase 3Recruiting
NCT00713011BayerAdalat XL

Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

Start: Nov 2008Est. completion: Mar 20090
Phase 3Withdrawn
NCT02552277CelularityPDA-002

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

Start: Oct 2015Est. completion: Oct 2017
Phase 2Completed
NCT03165227Boehringer IngelheimBI 685509

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Start: Oct 2017Est. completion: Dec 201975 patients
Phase 1Completed
NCT03165240Boehringer IngelheimBI 690517

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Start: Oct 2017Est. completion: May 202062 patients
Phase 1Completed
NCT07444203Boehringer IngelheimSodium-glucose cotransporter 2 inhibitors

Transformative Research in Diabetic Nephropathy 2.0

Start: Nov 2025Est. completion: Nov 2028200 patients
N/ARecruiting
NCT03334318Providence TherapeuticsMean blood glucose

PERL Continuous Glucose Monitoring (CGM) Study

Start: Oct 2017Est. completion: Dec 2021
N/ACompleted

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,749 patients
9 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Kidney Diseases(17)Kidney Transplant Rejection(16)Acute Kidney Injury(16)